Clinical Genetic Testing for APOL1: Are we There Yet?

Area of Science:

• Nephrology
• Genetics
• Public Health

Background:

• End-stage renal disease (ESRD) disproportionately impacts African Americans, with a 2-4 times higher incidence compared to European Americans.
• Two specific variants of the apolipoprotein L1 (APOL1) gene (G1 and G2) are linked to a 7-10 fold increased risk of nondiabetic ESRD in this population.
• Inheriting two APOL1 risk variants increases the likelihood of developing ESRD at a younger age and experiencing chronic kidney disease progression.

Purpose of the Study:

• To address uncertainties regarding the proportion of individuals with high-risk APOL1 genotypes who develop ESRD.
• To investigate the precise mechanisms of APOL1-related kidney injury and its interaction with environmental factors and comorbidities.
• To inform the development of guidelines for APOL1 genetic testing in clinical care and population screening.

Main Methods:

• The abstract does not specify the methods used in the study.
• Research incorporating APOL1 status assessment is proposed to clarify current uncertainties.
• Community member perspectives are highlighted as essential for developing responsible approaches to genetic information dissemination.

Main Results:

• The abstract does not present specific results.
• The study aims to determine the proportion of individuals with high-risk APOL1 genotypes who will develop ESRD.
• Understanding APOL1 variant implications is crucial for managing kidney transplant protocols and potential genetic testing.

Conclusions:

• Widespread APOL1 genetic testing for ESRD risk is not yet recommended due to existing uncertainties.
• Further research is needed to understand APOL1's role in kidney disease, including mechanisms, environmental factors, and comorbidities.
• Informed consent and counseling are essential if APOL1 testing is considered for high-risk individuals or as part of transplant protocols.